BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 26419843)

  • 21. Lymphatic flow is mostly preserved after sentinel lymph node biopsy in primary cutaneous malignant melanoma.
    Yokota K; Sawada M; Matsumoto T; Hasegawa Y; Kono M; Akiyama M
    J Dermatol Sci; 2015 May; 78(2):101-7. PubMed ID: 25771166
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Factors that predict the presence of sentinel lymph node metastasis in patients with melanoma.
    McMasters KM; Wong SL; Edwards MJ; Ross MI; Chao C; Noyes RD; Viar V; Cerrito PB; Reintgen DS
    Surgery; 2001 Aug; 130(2):151-6. PubMed ID: 11490343
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Diversity of stage III melanoma in the era of sentinel lymph node biopsy.
    Egger ME; Callender GG; McMasters KM; Ross MI; Martin RC; Edwards MJ; Urist MM; Noyes RD; Sussman JJ; Reintgen DS; Stromberg AJ; Scoggins CR
    Ann Surg Oncol; 2013 Mar; 20(3):956-63. PubMed ID: 23064795
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sentinel lymph nodes containing very small (<0.1 mm) deposits of metastatic melanoma cannot be safely regarded as tumor-negative.
    Murali R; DeSilva C; McCarthy SW; Thompson JF; Scolyer RA
    Ann Surg Oncol; 2012 Apr; 19(4):1089-99. PubMed ID: 22271204
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Lymphatic invasion identified by monoclonal antibody D2-40, younger age, and ulceration: predictors of sentinel lymph node involvement in primary cutaneous melanoma.
    Niakosari F; Kahn HJ; McCready D; Ghazarian D; Rotstein LE; Marks A; Kiss A; From L
    Arch Dermatol; 2008 Apr; 144(4):462-7. PubMed ID: 18427039
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stromal PD-L1 Expression Is Associated With Better Disease-Free Survival in Triple-Negative Breast Cancer.
    Li X; Wetherilt CS; Krishnamurti U; Yang J; Ma Y; Styblo TM; Meisel JL; Peng L; Siddiqui MT; Cohen C; Aneja R
    Am J Clin Pathol; 2016 Oct; 146(4):496-502. PubMed ID: 27686176
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Highly sensitive multivariable assay detection of melanocytic differentiation antigens and angiogenesis biomarkers in sentinel lymph nodes with melanoma micrometastases.
    Vitoux D; Mourah S; Kerob D; Verola O; Basset-Seguin N; Baccard M; Schartz N; Ollivaud L; Archimbaud A; Servant JM; Revol M; Toubert ME; Podgorniak MP; Plassa F; Porcher R; Lebbé C
    Arch Dermatol; 2009 Oct; 145(10):1105-13. PubMed ID: 19841396
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting the PD1/PD-L1 axis in melanoma: biological rationale, clinical challenges and opportunities.
    Merelli B; Massi D; Cattaneo L; Mandalà M
    Crit Rev Oncol Hematol; 2014 Jan; 89(1):140-65. PubMed ID: 24029602
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Treatment outcome of PD-1 immune checkpoint inhibitor in Asian metastatic melanoma patients: correlative analysis with PD-L1 immunohistochemistry.
    Cho J; Ahn S; Yoo KH; Kim JH; Choi SH; Jang KT; Lee J
    Invest New Drugs; 2016 Dec; 34(6):677-684. PubMed ID: 27491654
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and histopathological risk factors to predict sentinel lymph node positivity, disease-free and overall survival in clinical stages I-II AJCC skin melanoma: outcome analysis from a single-institution prospectively collected database.
    Mandalà M; Imberti GL; Piazzalunga D; Belfiglio M; Labianca R; Barberis M; Marchesi L; Poletti P; Bonomi L; Novellino L; Di Biagio K; Milesi A; Guerra U; Tondini C
    Eur J Cancer; 2009 Sep; 45(14):2537-45. PubMed ID: 19553103
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Accuracy of the non-sentinel node risk score (N-SNORE) in patients with cutaneous melanoma and positive sentinel lymph nodes: a retrospective study.
    Feldmann R; Fink AM; Jurecka W; Rappersberger K; Steiner A
    Eur J Surg Oncol; 2014 Jan; 40(1):73-6. PubMed ID: 24075029
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumor-infiltrating lymphocytes predict sentinel lymph node positivity in patients with cutaneous melanoma.
    Taylor RC; Patel A; Panageas KS; Busam KJ; Brady MS
    J Clin Oncol; 2007 Mar; 25(7):869-75. PubMed ID: 17327608
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Sentinel lymph node biopsy in melanoma patients with clinically negative regional lymph nodes--one institution's experience.
    Nowecki ZI; Rutkowski P; Nasierowska-Guttmejer A; Ruka W
    Melanoma Res; 2003 Feb; 13(1):35-43. PubMed ID: 12569283
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Small and Isolated Immunohistochemistry-positive Cells in Melanoma Sentinel Lymph Nodes Are Associated With Disease-specific and Recurrence-free Survival Comparable to that of Sentinel Lymph Nodes Negative for Melanoma.
    LeBlanc RE; Barton DT; Li Z; Angeles CV; Ernstoff MS; Bagley E; Wimmer D; Wong SL; Barth RJ; Shirai K; Yan S
    Am J Surg Pathol; 2019 Jun; 43(6):755-765. PubMed ID: 31091203
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Intraoperative evaluation of sentinel lymph nodes for metastatic melanoma by imprint cytology.
    Creager AJ; Shiver SA; Shen P; Geisinger KR; Levine EA
    Cancer; 2002 Jun; 94(11):3016-22. PubMed ID: 12115392
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Feasibility and technical problems of sentinel node analysis in melanoma].
    Mebazaa A; Kerob D; Toubert ME; Verola O; Servant JM; Baccard M; Billotey C; Bustamante K; Vandici FO; Basset-Seguin N; Ollivaud L; Morel P; Lebbé C
    Ann Chir Plast Esthet; 2007 Feb; 52(1):14-23. PubMed ID: 17141391
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PD-L1 Copy Number Variation Does Not Correlate With PD-L1 Expression or Response to Anti-PD-1 Immunotherapy In Patients With Advanced Melanomas.
    Pérottet J; Le Goff E; Legoupil D; Quéré G; Schick U; Marcorelles P; Uguen A
    Appl Immunohistochem Mol Morphol; 2020 Feb; 28(2):161-165. PubMed ID: 32044885
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Does the method of biopsy affect the incidence of sentinel lymph node metastases?
    Newman EL; Kahn A; Diehl KM; Cimmino VM; Kleer CA; Chang AE; Newman LA; Sabel MS
    Breast J; 2006; 12(1):53-7. PubMed ID: 16409587
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The analysis of the outcomes and factors related to iliac-obturator involvement in cutaneous melanoma patients after lymph node dissection due to positive sentinel lymph node biopsy or clinically detected inguinal metastases.
    Zdzienicki M; Rutkowski P; Nowecki ZI; van Akkooi AC; Michej W; Dziewirski W; Świtaj T; Pieńkowski A; Sałamacha M; Bylina E; Eggermont AM
    Eur J Surg Oncol; 2013 Mar; 39(3):304-10. PubMed ID: 23298828
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The benefit of a sentinel lymph node biopsy and adjuvant therapy in thick (>4 mm) melanoma: multicenter, retrospective study of 291 Japanese patients.
    Fujisawa Y; Otsuka F;
    Melanoma Res; 2012 Oct; 22(5):362-7. PubMed ID: 22713797
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.